United Therapeutics Corp
NASDAQ:UTHR 3:59:59 PM EDT
| Market Cap (Intraday) | 8.93B |
| Current PE | 18.96 |
| Forward PE | 16.28 |
| 2yr Forward PE | 12.17 |
| 10-Day MA | $203.97 |
| 50-Day MA | $199.14 |
| 200-Day MA | $180.79 |
United Therapeutics Corp Stock, NASDAQ:UTHR
1040 Spring Street, Silver Spring, Maryland 20910
United States of America
Phone: +1.301.608.9292
Number of Employees: 950
Description
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It also involves in the research and development of new indications and delivery devices for its product and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.